Skip header and navigation

1 records – page 1 of 1.

A cost-outcome analysis of adjuvant postmastectomy locoregional radiotherapy in premenopausal node-positive breast cancer patients.

https://arctichealth.org/en/permalink/ahliterature196689
Source
Int J Radiat Oncol Biol Phys. 2000 Nov 1;48(4):977-82
Publication Type
Article
Date
Nov-1-2000
Author
P. Dunscombe
R. Samant
G. Roberts
Author Affiliation
Northeastern Ontario Regional Cancer Centre, Sudbury, Ontario, Canada. pdunscombe@neorcc.on.ca
Source
Int J Radiat Oncol Biol Phys. 2000 Nov 1;48(4):977-82
Date
Nov-1-2000
Language
English
Publication Type
Article
Keywords
Breast Neoplasms - economics - radiotherapy - surgery
Canada
Cost-Benefit Analysis
Female
Humans
Lymphatic Metastasis
Mastectomy
Premenopause
Quality-Adjusted Life Years
Radiotherapy, Adjuvant - economics
Abstract
To calculate cost-effectiveness and cost-utility ratios for adjuvant postmastectomy locoregional radiotherapy in premenopausal node-positive breast cancer patients and to place these ratios in the context of generally accepted medical expenditures.
A spreadsheet-based activity costing model using 1997 Canadian (cdn) capital, operating, and administrative costs has been used to identify, from the institutional perspective, the incremental cost of adding radiotherapy to surgery and chemotherapy for this group of patients. Outcome data were derived from two recently published clinical trials and were converted to discounted incremental life years and quality-adjusted life years gained. Recommended health economics principles were employed in the quantification of both costs and outcomes, and a sensitivity analysis was performed. Three referenced publications provide a context within which to evaluate the calculated cost-effectiveness and cost-utility ratios.
The incremental cost of adjuvant radiotherapy for this group of patients is calculated to be approximately $7,000cdn in 1997 Canadian dollars and in the Canadian socialized health-care environment. Based on published work the discounted incremental outcome benefit is calculated to be 0.5 life years or 0.45 quality-adjusted life years at ten years. Thus, cost effectiveness and cost-utility ratios are estimated to be $14,000cdn and $15,600cdn, respectively.
Within the context of generally accepted medical expenditures, adjuvant postmastectomy locoregional radiotherapy for premenopausal node-positive breast cancer patients would be regarded as a cost-effective treatment strategy.
Notes
Comment In: Int J Radiat Oncol Biol Phys. 2001 Aug 1;50(5):137611503614
PubMed ID
11072153 View in PubMed
Less detail